Volume 2, Issue 11 : Risks and Benefits of SGLT-2 Inhibitor Agents
e-Diabetes Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with diabetes. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 2, Issue 11)
Nurses and health care professionals involved in the care of patients with diabetes.
After participating in this activity, the participant will demonstrate the ability to:
• Describe the glucose lowering effects of SGLT-2 inhibitors.
• Discuss the cardiovascular outcome data of empagliflozin with regards to its impact on patient care.
• Discuss common side effects of SGLT-2 inhibitors and how to avoid them.
Anne Peters, MD
Keck School of Medicine of the University of Southern California
Director, USC Clinical Diabetes Program
Los Angeles, California
- 0.50 ANCC
- 0.50 Attendance